A single-center retrospective study of salvage allogeneic hematopoietic stem cell transplantation pretreated with MeCBA regimen for refractory/relapsed acute myeloid leukemia
10.3760/cma.j.cn121090-20231027-00234
- VernacularTitle:MeCBA预处理方案异基因造血干细胞移植挽救性治疗难治/复发急性髓系白血病的单中心回顾性研究
- Author:
Fangfang YUAN
1
;
Yongqi WANG
;
Minghui LI
;
Gangping LI
;
Ziye LI
;
Ruihua MI
;
Qingsong YIN
;
Yuewen FU
;
Xudong WEI
Author Information
1. 河南省肿瘤医院（郑州大学附属肿瘤医院）血液科，郑州 450008
- From:
Chinese Journal of Hematology
2024;45(5):500-504
- CountryChina
- Language:Chinese
-
Abstract:
Thirty refractory relapsed acute myeloid leukemia (R/R AML) patients who received salvage allo-HSCT with MeCBA conditioning regimen from January 2018 to June 2022 at Henan Cancer Hospital were included, and their clinical data were reviewed. There were 16 males and 14 females among the 30 patients with a median age of 37 (16-53) years. There were 3 sibling allograft donor transplants, 1 unrelated donor transplant, and 26 haplotype transplants. The median course of pre-transplant chemotherapy was 4 (3-22). The time of neutrophil engraftment was 14 (9-22) days and 18 (10-40) days for platelet. The 30-day cumulative incidence of neutrophil engraftment was 100% and the 100-day cumulative incidence of platelet engraftment was 96.7% (95% CI 85.4% -97.5% ). 22 (73.3% ) patients experienced grade 1-2 gastrointestinal reactions, and there was no grade 3-4 organ toxicity. With a median follow-up of 37.1 months, the overall survival (OS) rate, event-free survival (EFS) rate, cumulative recurrence rate (CIR), and non-recurrence mortality (NRM) rate at 3 years after transplantation were 70.0% (95% CI 50.3% -83.1% ), 65.3% (95% CI 44.8% -79.8% ), 21.2% (95% CI 9.2% -44.4% ) and 16.7% (95% CI 7.3% -35.5% ), respectively.
